Magnetic Resonance Imaging and Spectroscopy of the Prostate

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00590993

Enrollment

1005

Registered

2008-01-11

Start date

2000-12-31

Completion date

2013-02-28

Last updated

2023-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

MRSI, MRI, Prostate Cancer

Brief summary

Past studies have shown that MRI is useful for staging prostate cancer. This study will use magnetic resonance spectroscopic imaging (MRSI) to obtain more information. MRSIs with MRIs help doctors locate prostate cancer and determine the extent of tumor before deciding on treatment. This study looks at structural and chemical properties of prostates in prostate cancer patients before and after treatment.

Interventions

OTHERMRI and MRSI

Compare treatment impact when using MRI and MRSI

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* prostate cancer patients willing to undergo a MRI and MRSI exam

Exclusion criteria

* patients with prostate cancer and bone or lymph node metastasis * patients who can not have an MRI exam

Design outcomes

Primary

Measure	Time frame
Determine added value in combining MRSI and MRI in prostate cancer treatment	3 hours

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026